Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin and Low-dose Ara-C in AML
NCT01056523Phase 2Completed
- Sponsor
- Jewish General Hospital
- Start
- Jan 2010
- Primary completion
- Jan 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of ribavirin in acute myeloid leukemia (AML), sponsored by Jewish General Hospital. Started Jan 2010; status: completed.
02
Drugs
ribavirin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01056523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056523.